Role of CD4+CD8+ T cells in liver transplantation.

Menal Sodh*

Department of Immunology, Kings College, London, UK

Introduction

Liver transplantation is a life-saving procedure for patients with end-stage liver disease and acute liver failure. It involves the replacement of a diseased or damaged liver with a healthy liver from a deceased or living donor. Despite significant advancements in transplant medicine, immune-mediated rejection remains a major concern that can impact the success of the procedure. Among the various immune cell populations involved in liver transplantation, CD4+CD8+ T cells have emerged as intriguing players with a complex role in the process [1].

Basics of CD4+CD8+ T cells

CD4+CD8+ T cells, also known as double-positive T cells, are a unique subset of T lymphocytes characterized by co-expression of both CD4 and CD8 surface markers. Conventionally, T cells differentiate into either CD4+ or CD8+ single-positive subsets during their maturation in the thymus. However, a small fraction of T cells undergoes aberrant differentiation, resulting in the simultaneous expression of both CD4 and CD8 molecules. The functional significance of CD4+CD8+ T cells remains somewhat elusive, but they are thought to represent an intermediate stage in T cell development. While their exact role in the immune system is not fully understood, research has shown that they possess distinct biological properties and can exert both helper and cytotoxic functions [2].

CD4+CD8+ T cells and liver transplantation

In the context of liver transplantation, the role of CD4+CD8+ T cells becomes particularly intriguing. These cells have been identified in the liver microenvironment during transplant rejection, and their presence has been associated with both beneficial and detrimental effects. Some studies have suggested that CD4+CD8+ T cells play a significant role in promoting acute rejection following liver transplantation. These cells have been found to infiltrate the allograft and contribute to tissue damage through cytotoxic activity. The potential to exert both CD4+ helper and CD8+ cytotoxic functions allows CD4+CD8+ T cells to mediate graft rejection through various mechanisms. Their ability to simultaneously release pro-inflammatory cytokines and cytolytic molecules makes them potent contributors to tissue injury [3].

On the other hand, CD4+CD8+ T cells have also been associated with tolerance induction and immune regulation in specific experimental models. It has been observed that these cells can suppress immune responses and promote tolerance to the transplanted organ. By releasing regulatory cytokines such as interleukin-10 (IL-10) and transforming growth factor-beta (TGF-beta), CD4+CD8+ T cells may dampen excessive immune reactions, thereby protecting the graft from rejection [4].

Chronic rejection, characterized by gradual graft dysfunction, is a long-term complication after liver transplantation. Studies have reported an accumulation of CD4+CD8+ T cells in chronically rejected liver allografts. The precise role of these cells in chronic rejection is not fully understood, but their presence suggests their involvement in the ongoing immune response against the graft. The presence of CD4+CD8+ T cells in the liver microenvironment can potentially serve as a biomarker for transplant outcomes. By monitoring their levels, clinicians may gain insights into the immunological status of the graft and assess the risk of rejection or tolerance development. Moreover, understanding the mechanisms that govern CD4+CD8+ T cell function in liver transplantation could open avenues for targeted therapeutic interventions to prevent or treat rejection episodes [5].

Conclusion

CD4+CD8+ T cells in liver transplantation represent a double-edged sword, playing a complex role in allograft rejection and immune regulation. Their unique ability to exert both helper and cytotoxic functions makes them intriguing targets for further research in the field of transplantation immunology. By unraveling the underlying mechanisms that govern the behavior of these cells, we can potentially devise innovative strategies to improve transplant outcomes and promote long-term graft acceptance. As the field of immunology advances, the enigma surrounding CD4+CD8+ T cells in liver transplantation may eventually be unraveled, paving the way for more successful and tolerable liver transplant procedures in the future.

References

1. Welsh RM, Che JW, Brehm MA, et al. Heterologous immunity between viruses. Immunol Rev 2010; 235: 244-66.
2. Burrows SR, Khanna R, Burrows JM, et al. An alloresponse in humans is dominated by cytotoxic T lymphocytes (CTL) cross-reactive with a single Epstein–Barr virus CTL epitope: implications for graft-versus-host disease. J Exp Med 1994; 179: 1155-61.

***Correspondence to:** Menal Sodh, Department of Immunology, Kings College, London, UK, E-mail: menals@kcl.ac.uk

***Received:** 26-July-2023, Manuscript No. AAICR-23-108994; **Editor assigned:** 28-July-2023, Pre QC No. AAICR-23-108994(PQ); **Reviewed:** 11-Aug-2023, QC No. AAICR-23-108994; **Revised:** 16-Aug-2023, Manuscript No. AAICR-23-108994(R); **Published:** 23-Aug-2023, DOI:10.35841/aaicr-6.4.157*

***Citation:** Sodh M. Role of CD4+CD8+ T cells in liver transplantation. Immunol Case Rep. 2023;6(4):157*

3. Morris GP, Allen PM. Cutting edge: highly alloreactive dual TCR T cells play a dominant role in graft-versus-host disease. J Immunol 2009; 182: 6639-43.

4. Morris GP, Uy GL, Donermeyer D, et al. Dual receptor T cells mediate pathologic alloreactivity in patients with acute graft-versus-host disease. Sci Transl Med 2013; 5(188): 188ra74–ra74.

5. Berard M, Tough DF. Qualitative differences between naïve and memory T cells. Immunology 2002; 106: 127-38.